Assessment of Cardio-Oncology Knowledge and Practice among Healthcare Providers in Saudi Arabia: A Comprehensive Nationwide Survey

Assessment of Cardio-Oncology Knowledge and Practice among Healthcare Providers in Saudi Arabia: A Comprehensive Nationwide Survey | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Assessment of Cardio-Oncology Knowledge and Practice among Healthcare Providers in Saudi Arabia: A Comprehensive Nationwide Survey Hisham A. Badreldin, Nada Alsuhebany, Lama Alfehaid, Mohammed Alzahrani, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4959562/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 31 Dec, 2024 Read the published version in Cardio-Oncology → Version 1 posted 7 You are reading this latest preprint version Abstract Introduction: The evolving field of oncology necessitates effective management of cancer-related cardiovascular diseases. In Saudi Arabia, the incidence of cancer is rising, and there is a critical need for cardio-oncology services to address cancer treatment-related cardiovascular toxicity. This study aimed to evaluate the knowledge and practices of healthcare providers (HCPs) in Saudi Arabia regarding cardio-oncology. Methods: A cross-sectional study was conducted from January to April 2024 using an online survey targeting cardiologists, oncologists, and clinical pharmacists. The survey assessed demographics, perceptions of cardio-oncology, availability of services, and current practices. Data were analyzed using descriptive statistics, chi-squared tests, and bivariate analyses. Results: The survey received responses from 116 HCPs, including cardiologists (63.79%), oncologists (23.28%), and clinical pharmacists (12.93%). Most participants had over six years of experience, and only one had formal cardio-oncology training. While 84.48% recognized the importance of managing cardiac complications in cancer patients, only 42.24% were familiar with existing guidelines. Limited training programs and institutional resources were significant barriers to implementing cardio-oncology services. Despite agreement on the need for cardiotoxicity management, only one-third recommended cardioprotective agents as standard care. Conclusion: There is a notable deficiency in formal training and resources for cardio-oncology in Saudi Arabia. To bridge this gap, integrating cardio-oncology into training programs, establishing institutional guidelines, and adopting multidisciplinary care models are crucial. These measures will enhance the quality of care for cancer patients and improve their cardiovascular outcomes. Figures Figure 1 Figure 2 Figure 3 Introduction The oncology field is witnessing a rapid evolution in systemic therapy regimens and guidelines globally[ 1 ]. In 2020 alone, 17,631 newly diagnosed cases of cancer were reported to the Saudi Cancer Registry, with the most common being breast, colorectal then thyroid cancers[ 2 ]. With improvements in cancer management resulting in decreasing cancer-related mortality rates, the management of cardiovascular diseases and accessibility to cardiovascular care have become increasingly paramount[ 3 ]. Despite advancements in medical care, cancer and cardiovascular diseases remain prominent causes of mortality globally[ 4 ]. As cancer and cardiovascular disease both share similar risk factors, such as increasing age, smoking, alcohol use, and high BMI[ 5 – 8 ], this contributes to the rising prevalence of both diseases. This is further complicated by the fact that it has been well-established that cancer treatments can cause cancer treatment-related cardiovascular toxicity (CTR-CVT)[ 9 , 10 ]. Since then, it has been suggested that cardiotoxic cancer medications can be divided into drugs that can potentially cause irreversible damage (Type I) and drugs that predominantly induce reversible dysfunction (Type II)[ 11 ]. Cardio-oncology has emerged as an expanding specialty dedicated to providing cardiovascular care for both active cancer patients and cancer survivors in direct response to the increasing requirements of this population[ 1 ]. The scope of cardio-oncology encompasses optimizing pre-cancer treatment, diagnosing, and managing cardiac complications resulting from cancer treatment both during and after the completion of cancer therapy. Although numerous cardio-oncology programs have emerged to address these demands, they remain predominantly confined to larger institutions, often serving as academic referral centers. Over the years, several international organizations, including the American Society of Clinical Oncology (ASCO), the European Society of Cardiology (ESC), and the National Comprehensive Cancer Network (NCCN), have issued several position statements and guidelines pertaining to the detection and management of cancer treatment-related cardiac dysfunction (CTRCD)[ 11 – 13 ]. However, cardio-oncology is still an emerging field. Due to a lack of training programs, it is unclear how well-trained healthcare providers (HCPs) are in this subspecialty. In a survey of 106 cardiovascular specialists in the United States, published in the Journal of American College of Cardiology, over 43% of respondents had no dedicated cardio-oncology training programs for cardiology fellows in their institutions[ 14 ]. Notably, in Saudi Arabia, cardio-oncology programs have been limitedly implemented thus far, and few to no formal training programs in the field are available. Thus, this research aims to assess the practical knowledge of HCPs, including cardiologists, oncologists, and clinical pharmacists, on cardio-oncology in Saudi Arabia. This would inform healthcare providers on how to better improve the quality of life of their patients and the care provided to them. Methods Study Design and Subjects A cross-sectional study was conducted in Saudi Arabia between January 2024 and April 2024. An online survey was created in English using Google Forms and distributed via email and social media platforms such as WhatsApp platform. The survey targeted physicians and clinical pharmacists specializing in oncology or cardiology. The survey was accompanied by a cover letter that described the research study's objective and targeted population, and participants were given access to the survey after accepting participation. The survey was created by two oncologists and two cardiologists specializing in cardio-oncology. It had been previously validated and used internationally in a study conducted by Peng et al. in 2019. The survey was obtained with the corresponding author's permission[ 15 ]. The study received Institutional Review Board (IRB) approval from King Abdullah International Medical Research Center at National Guard Health Affairs in Riyadh, Saudi Arabia (IRB/2930/23). Questionnaire Items The survey comprised seven sections, including multiple-choice and Likert scale questions and two clinical scenarios. It consisted of a total of 45 questions, with 13 of them for oncologists and five for cardiologists. The first section collected the participants’ demographics and respondents. The second section evaluated the participants’ perceptions of cardio-oncology, for instance, inquiring about one’s definition of “cardio-oncology”. The third section assessed the availability of cardio-oncology services at participants’ institutions. The fourth section collected opinions regarding the current practices in the cardio-oncology field. It aimed to evaluate the perceived importance of oncologists in considering cardiotoxicity during different stages of cancer therapy, such as planning, utilization, and completion, and how it affects their decision-making processes. It also assessed participants’ opinions on whether cancer patients would benefit from cardiologists' involvement and cardio-oncology clinics. The fifth section of the questionnaire is directed explicitly to cardiologists. This section assessed cardiologists' knowledge and comfort level in recognizing and managing cardiotoxicity. Additionally, it aimed to determine their perception of the skills and expertise possessed by their oncology colleagues in dealing with cardiotoxicity-related issues. The following section of the questionnaire was designed solely for oncologists to assess their knowledge and comfort level in identifying and managing cardiotoxicity. In addition, it aimed to determine their perspective on the skill of their cardiology colleagues in dealing with cardiotoxicity-related cancer therapy. The last section presented two clinical scenarios of common cardiotoxicity issues in oncology to assess participants' ability to apply their knowledge. Statistical Analysis Descriptive quantitative analysis was generated via the “response” feature in Google Forms. Chi-squared test was used to compare categorical variables, and bivariate analysis was used to examine associations between the dependent and independent variables. The response rate was not obtainable, given the survey was distributed online. Statistical analyses were conducted using Excel software version 16.88. Results Demographics of respondents and experience in practice A total of 116 HCPs in Saudi Arabia participated in the survey. Most respondents were cardiologists (63.79%), followed by oncologists (23.28%), and clinical pharmacists specializing in cardiology and oncology (12.93%). Nearly more than half of the respondents were from the central region of Saudi Arabia (67.24%). The majority of participants had over six years of experience (80.68%). Out of the respondents, only one physician received formal training in cardio-oncology. Additionally, 87.07% of the practitioners worked in tertiary hospitals (Table 1 ). Table 1 Demographics of healthcare professionals surveyed (n = 116) Region n % Central region 78 67.24 Eastern region 18 15.52 Western region 11 9.48 Northern region 4 3.45 Southern region 5 4.31 Specialty Cardiology phis 74 63.79 Oncology/hematology 27 23.28 Clinical Pharmacist in cardiology field 8 6.90 Clinical Pharmacist in oncology/hematology field 7 6.03 Current position Consultant (physician or pharmacist) 88 48.35 Staff physician 8 4.40 Senior pharmacist 5 2.75 Fellow 12 6.59 Medical Resident 3 1.65 Years practice of consultant (physician or pharmacist) 0–5 years 17 19.32 6–10 years 19 21.59 11–20 years 32 36.36 > 20 years 20 22.73 Practice location description Tertiary care hospital 101 87.07 Secondary hospital 11 9.48 Private clinic/hospital 4 3.45 Percentage of time spent on clinical research Less than 10% 60 51.72 10–20% 31 26.72 20–30% 15 12.93 30–40% 4 3.45 40–50% 1 0.86 More than 50% 5 4.31 Perception of cardio-oncology and cardiotoxicity Regarding the HCP’s perception towards cardio-oncology, the respondents had the chance to respond to this question with multiple choice questions where multiple answers were accepted. The majority of respondents believed cardio-oncology means managing cancer patients who are experiencing cardiac complications secondary to cancer therapy (84.48%). Furthermore, more than (80%) believed cardio-oncology is about recognizing patients at high risk of developing cardiotoxicity from cancer treatment and diagnosing cardiotoxicity induced by cancer treatment (83.62 and 82.76%, respectively) (Fig. 1 ). Regarding the HCPs perception towards the most significant risk of cardiotoxicity induced by cancer treatment,=70.69%) of respondents believe that targeted agents (such as trastuzumab) induced cardiotoxicity could be experienced during cancer treatment. In addition, 56.90% believe that chemotherapy-induced cardiotoxicity could develop during cancer treatment (Table 2 ). Table 2 Perceptions of cardiotoxicity risk The greatest risk of experiencing cardiotoxicity from chemotherapy (e.g. anthracyclines), n (%) During cancer treatment (chemotherapy and/or targeted agents) 66 (56.9) One-year post-cancer therapy (short-term risk) 42 (36.21) One to five years post-cancer therapy 48 (41.38) Greater than five years post-cancer therapy (long-term risk) 52 (44.83) The greatest risk of experiencing cardiotoxicity from targeted therapies (e.g. trastuzumab), n (%) During cancer treatment (chemotherapy and/or targeted agents) 82 (70.69) One year post-cancer therapy (short-term risk) 26 (22.42) One to five years post-cancer therapy 39 (33.63) Greater than five years post-cancer therapy (long-term risk) 32 (27.59) Almost 42.24% of respondents reported being familiar with guidelines from expert societies on the directions and management of cardiovascular toxicity. Out of the reported societies, the ESC was the most recognized guideline (58.93%) by the respondents (Fig. 2 ). Availability of cardio-oncology services at respondents' institution This survey assessed the availability of educational programs in cardio-oncology. The most frequent answer regarding educational programs was “there is little cardiology training for clinical cardiology fellows” (36.21%). Interestingly, 31.9% of respondents reported the lack of program availability at all. Regarding cardio-oncology services offered currently at respondents' institutions, almost half of the respondents reported providing such services on a consultation-based model (55.18%). Reflecting on the potential obstacles to the development of cardio-oncology units, “limited interest” was the most frequent answer (40.52%) reported by the respondents, followed by “limited funding” and “limited infrastructure” (28.45%, 25%) (Table 3 ). Table 3 Availability of cardio-oncology services at respondents' institution Education programs are available in the field of cardio-oncology, n (%) There is little cardio-oncology training for clinical cardiology fellows 42 (36.21) Cardiology fellows are exposed to cardio-oncology during clinical rotations as part of the curriculum 9 (7.76) There are some lectures on cardio-oncology as part of the core curriculum or CME offerings 22 (18.97) Cardiology fellows can choose to spend time training with the oncology service, but this is not part of the core curriculum 6 (5.18) There is a dedicated cardio-oncology fellowship program (at least 6 months) 1 (0.87) I am unsure of available cardio-oncology programs 38 (32.76) No available programs at all 37 (31.9) Cardio-oncology services are currently offered Consultation service operated by general cardiologists for assessment and management of cardiotoxicity among cancer patients 64 (55.18) Physicians specialized in the field of cardio-oncology who are comfortable managing cardio-toxic side effects due to cancer therapy and can give recommendations for adjusting cancer therapy 3 (2.59) Clinical pharmacists in the field of cardio-oncology who are comfortable managing cardio-toxic side effects due to cancer therapy and can give recommendations for adjusting cancer therapy 5 (4.32) Cardio-oncology services are not currently present and there are no plans to add these services 10 (8.63) Cardio-oncology services are not currently present but there are plans to add these services within the year 7 (6.04) I am unsure of the available services 27 (23.28) Potential obstacles to the development of cardio-oncology units Limited funding 33 (28.45) Limited infrastructure 29 (25) Limited need 7 (6.04) Limited interest 47 (40.52) No obstacle 32 (27.59) Respondents' opinions towards current practice In the current study, both cardiologists and oncologists agreed on the importance of oncologists' consideration of cardiotoxicity when planning treatment plans (82.93% and 79.41% respectively). Furthermore, both specialist groups agreed on the importance of monitoring for possible cardiac adverse events during active cancer treatments (85.37% and 76.47% respectively). For cancer survivors, both groups agreed that oncologists should consider possible cardiac complications induced by cancer treatment exposure (58.54% and 55.88 respectively). Half of the respondents believed in the involvement of cardiologists in providing ongoing monitoring for cardiotoxicity, even if the patient has no clinical symptoms of cardiac issues. On a scale of 5, 34.15% of cardiologists strongly agree on using cardioprotective agents as a standard of care while 35% of oncologists were neutral about this statement. The majority of respondents (87.93%) thought that access to cardio-oncology services would not change the prognosis of cancer patients. In the setting of metastatic cancer, more cardiologists (7.32%) accepted a higher risk of cardiotoxicity (> 15% risk) compared to oncologists (0%) ( Figure. 3 ), However, both oncologists and cardiologists accepted cardiotoxicity ranging between 5–15%. Current Practice of Respondents Cardiologists' responses to the statement “I am knowledgeable about cardiovascular complications of cancer therapy” were mostly neutral (41.46%) followed by agreement (37.80%). There was an agreement among cardiologists about their comfort in treating cardiovascular complications induced by cancer therapy, where most of them responded as neutral, agree, and strongly agree (28.05%, 32.93%, and 25.61%, respectively). In addition to that, cardiologists' responses were mostly neutral when asked how oncologists are knowledgeable and comfortable with managing cardiovascular toxicities of cancer therapy (42.68% and 31.71%, respectively). Almost 40% of cardiologists reported that they sometimes prescribe cardiac medications to manage patients with cardiotoxicities as a result of cancer therapy. When it comes to oncologists' practice, almost 70% of oncologists feel comfortable treating cardiovascular toxicities induced by cancer therapy. In addition to that, 50% of them feel comfortable managing such cases. Furthermore, 44.12% of oncologists were neutral when asked “whether cardiologists are knowledgeable about these toxicities” and 35.29% agreed that cardiologists are comfortable managing such cases., Moreover, 33.8% of oncologists responded that they ask all cancer patients about cardiovascular risk factors prior to starting any cancer therapy. Similar to cardiologists, almost 40% of oncologists reported that they sometimes prescribe cardiac medications to patients with cardiovascular toxicities. Discussion The advancements in cancer therapy in recent years have contributed to increased overall survival in various cancer types, creating a population with emerging medical needs, including cardio-oncology care[ 16 ]. Several studies have been conducted to describe the cardio-oncology landscape among patients with cancer in Saudi Arabia. A single-center retrospective analysis that was conducted in Najran identified cardiac toxicity in around 15% of their cancer patient population[ 17 ]. Similarly, a larger retrospective analysis by Aljazairi and colleagues included over 1000 patients who received trastuzumab, pertuzumab, and bevacizumab; cardiovascular toxicities were detected in around 16% of their patient population[ 18 ]. A recent guideline update by the Saudi Heart Association expanded recommendations to focus on special populations, including oncology patients, to further accommodate the growing needs of patients living with cancer[ 19 ]. To our knowledge, this study is the first to capture the current state of cardio-oncology practices among healthcare providers in Saudi Arabia to help address knowledge gaps, educational and training needs in the country. Our survey was completed by 116 HCPs, most of whom were cardiology specialists. Most respondents had over five years of clinical experience and practiced in tertiary care institutions. Notably, out of the 116 responders, only one physician received formal cardio-oncology training, which reflects the current limited state of exposure to the field during residency and fellowship training. Most respondents were able to identify the growing role of cardio-oncology care and the major cardiovascular offenders, such as trastuzumab and anthracyclines. On the other hand, less than half of the respondents identified relevant information sources to refer back to, which is a considerable limitation to the provision of cardio-oncology care. This can be improved by setting institutional practice guidelines and introducing national and international practice guidelines in the field of cardio-oncology in training programs and academic curriculums. The American College of Cardiology established a framework for cardio-oncology subspecialty fellowship programs; it outlines the different levels of competency a program should offer, which range from a basic understanding of cardio-oncology concepts to rigorous coverage in cardio-oncology specialized clinics[ 20 ]. Multiple healthcare systems in the United States have shared successful experiences in implementing specialized training programs; several aspects can be adopted in Saudi Arabia, such as cross-training in specialized institutions and increasing focus on multidisciplinary care models[ 21 , 22 ]. The survey our study was adopted from Peng et al study, hence we compared results of our study Peng et al[ 15 ] which reveals several important similarities, and differences. While our study focused on a specific region, Saudi Arabia, and targeted cardiologists and oncologists, Peng et al.'s study had a broader geographic scope, including participants from 22 countries across multiple continents. This broader scope allowed Peng et al. to capture a more diverse range of practices and opinions, while our study provided a more focused insight into the cardio-oncology landscape within Saudi Arabia. In terms of demographics, both studies reported a higher participation rate among cardiologists than oncologists. When comparing perceptions of cardio-oncology and cardiotoxicity, both studies revealed that the majority of respondents recognized the importance of managing cardiac complications secondary to cancer therapy and the need for cardiologists' involvement in cancer care. However, Peng et al. found a more significant disparity between cardiologists and oncologists regarding when and how cardiologists should be involved in cancer patient care. Moreover, the availability of cardio-oncology services and training programs was a common concern in both studies. Peng et al. highlighted limited funding and infrastructure as significant barriers to the development of cardio-oncology clinics globally, whereas our study found that limited interest was a major obstacle in Saudi Arabia. Furthermore, the majority of respondents have highlighted the limited cardio-oncology services at their respective institutions. The barriers to establishing a specialized service were thought to be limited financial and administrative resources. Recommendations from a consolidated framework for implementation research (CFIR) model performed at an academic medical center in the United States may be utilized to help guide the implementation of cardio-oncology services in Saudi Arabia; this includes standardization of referral processes and integrating decision-making tools in electronic health records[ 23 ]. Another positive experience in implementing specialized cardio-oncology services was reported by the Iraqi Cardio-Oncology Program-Pharmacist (ICOP-Pharm). The ICOP model integrates experienced clinical pharmacists in direct patient care as a part of a multidisciplinary care team; this allowed better drug therapy optimization and helped cardiologists manage a larger number of patients[ 24 ]. Metastatic cancer disease survival has increased significantly over the last few years in which common cancer diseases such as metastatic colorectal, and breast cancers have median survival of more than 2–3 years[ 25 – 26 ]. The results of our study indicate that in the setting of metastatic cancer, a higher percentage of cardiologists were willing to accept a cardiotoxicity risk greater than 15%, whereas none of the oncologists were willing to accept this level of risk. This finding is particularly noteworthy as it suggests that oncologists may be less willing to accept higher cardiotoxicity risks in these patients because many of them can maintain a good quality of life during their extended survival period. In contrast, cardiologists might be more inclined to accept higher risks, potentially due to limited awareness of the significant improvements in survival rates and quality of life for these patients. This difference in perception demonstrates the need for better interdisciplinary communication and education to align treatment goals and risk assessments between cardiologists and oncologists, ensuring that patients receive the most appropriate care tailored to their long-term survival prospects. Survey domains evaluating current practices have shown a general agreement on considering potential cardiotoxicities in oncology patients and the involvement of cardiology in managing patients who develop toxicities. However, one-third of respondents actively recommend cardioprotective agents in the care process. The described practice is consistent with the ESC cardio-oncology guidelines, which suggests only considering cardioprotective strategies in high-risk subsets of patients based on small clinical trials[ 12 ]. Surprisingly, over 80% of responders thought that cardio-oncology care will not change cancer prognosis. In addition, there seems to be a gap in cardiovascular risk factor screenings in oncology patients undergoing therapy. These interesting results indicate that cancer and cardiovascular disease are viewed as separate disease states rather than a part of the oncology disease continuum; this further confirms the need for robust cardio-oncology services since several large studies have shown increased cardiovascular disease incidence and mortality in patients with cancer compared to the general population[ 16 , 27 – 34 ]. This nationwide study has several limitations. First, the survey was distributed on a large scale via link distribution, limiting our ability to assess the survey response rate. The majority of respondents were practicing in academic and tertiary care centers in the central region of Saudi Arabia, which limits the generalizability of these results to smaller healthcare settings. Conclusion The study highlights a significant knowledge gap and limited exposure to cardio-oncology among HCPs in Saudi Arabia. Despite recognizing the importance of managing cardiotoxicity in cancer patients, formal training and comprehensive cardio-oncology services remain limited. Implementing institutional guidelines, integrating cardio-oncology into medical education, and adopting multidisciplinary care models are essential to improve patient outcomes and address the growing needs of cancer patients at risk of cardiovascular complications. Declarations Ethical Approval The study received Institutional Review Board (IRB) approval from King Abdullah International Medical Research Center at National Guard Health Affairs in Riyadh, Saudi Arabia (IRB/2930/23). All participants consented when they filled out the survey. Funding No financial support of any form was received in connection with this study. Author Contribution HAB contributed to the concept of the research; NA distributed the survey and wrote the abstract, introduction, discussion, and conclusion. also, has critiqued the whole manuscript; LA distributed the survey and wrote the method part, and critiqued the whole manuscript; MAZ did the analysis and wrote the result part; MAD wrote the discussion part; AMA distributed the survey, and critiqued the whole manuscript; JA distributed the survey, and wrote the method part; DE distributed the survey, and wrote the introduction part; KA distributed the survey, and critiqued the whole manuscript; AND all authors reviewed the submitted manuscript Data Availability The data that support the findings of this study are available from the corresponding author on reasonable request. References Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J. 2019;40:3898–900. 10.1093/eurheartj/ehz781 . Saudi Cancer Registry. Cancer Incidence Report in Saudi Arabia. Ministry of Health; 2020. Sturgeon KN, Deng L, Bluethman SL, et al. A population based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889–97. 10.1093/eurheartj/ehz766 . Global Health Estimates. 2019: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. Geneva, World Health Organization; 2020. Tran K, Bao et al. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet , Volume 400, Issue 10352, 563–591. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11–17;364(9438):937 – 52. 10.1016/S0140-6736(04)17018-9 . PMID: 15364185. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097–108. 10.1161/CIRCRESAHA.111.246876 . PMID: 22499900; PMCID: PMC3366686. Von Hoff DD, Layard MW, Basa P, Jr DAVIS, Von Hoff HL, Rozencweig AL, M., Muggia FM. Risk factors for doxorubicin-lnduced congestive heart failure. Ann Intern Med. 1979;91(5):710–7. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820-6. 10.1200/JCO.2005.13.300 . PMID: 16258084. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900-2. 10.1200/JCO.2005.05.827 . PMID: 15860848. Saro H, Armenian et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. JCO 35, 893–911(2017). 10.1200/JCO.2016.70.5400 Lyon AR, López-Fernández T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J. 2023;44(18):1621. 10.1093/eurheartj/ehad196] . Eur Heart J. 2022;43(41):4229–4361. doi:10.1093/eurheartj/ehac244. Cardiovascular Health and Risk Management in Cancer Survivors. (2020). Journal of the National Comprehensive Cancer Network. J Natl Compr Canc Netw , 18(7.5), 1004–1006. Retrieved Mar 25, 2024, from https://doi.org/10.6004/jnccn.2020.5004 Barac A, Murtagh G, Carver J, et al. Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol. 2015 Jun;65(25):2739–46. https://doi.org/10.1016/j.jacc.2015.04.059 . Peng J, Rushton M, Johnson C, et al. An international survey of healthcare providers' knowledge of cardiac complications of cancer treatments. Cardiooncology. 2019;5:12. 10.1186/s40959-019-0049-2 . Published 2019 Sep 2. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97. 10.1093/eurheartj/ehz766 . Badheeb AM, Ahmed F, Alzahrani HA, Badheeb MA, Obied HY, Seada IA. Cancer Therapy-Related Cardiotoxicity: A Comprehensive Retrospective Analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. 10.7759/cureus.41287 . Published 2023 Jul 2. Al-Jazairi AS, Bahammam N, Aljuaid D et al. Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system. Cardiooncology. 2023;9(1):35. Published 2023 Sep 25. 10.1186/s40959-023-00184-z Al Habeeb W, Tash A, Elasfar A, et al. 2023 National Heart Center/Saudi Heart Association Focused Update of the 2019 Saudi Heart Association Guidelines for the Management of Heart Failure. J Saudi Heart Assoc. 2023;35(1):71–134. 10.37616/2212-5043.1334 . Published 2023 May 25. Alvarez-Cardona JA, Ray J, Carver J, et al. Cardio-Oncology Education and Training: JACC Council Perspectives. J Am Coll Cardiol. 2020;76(19):2267–81. 10.1016/j.jacc.2020.08.079 . Fradley MG. Cardio-Oncology Fellowship Training and Education. Curr Treat Options Cardiovasc Med. 2019;21(6):27. 10.1007/s11936-019-0733-4 . Published 2019 May 18. Tuzovic M, Brown SA, Yang EH, et al. Implementation of Cardio-Oncology Training for Cardiology Fellows. JACC CardioOncol. 2020;2(5):795–9. 10.1016/j.jaccao.2020.11.003 . Published 2020 Dec 15. Clouser JM, McMullen CA, Adu AK, Wells G, Arbune A, Li J. Using the consolidated framework for implementation research (CFIR) to guide implementation of cardio-oncology services. Learn Health Syst. 2023;8(2):e10402. 10.1002/lrh2.10402 . Published 2023 Dec 13. Yaseen IF, Farhan HA. Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study. Front Cardiovasc Med. 2022;9:972455. 10.3389/fcvm.2022.972455 . Published 2022 Sep 29. Valachis A, Carlqvist P, Ma Y, Szilcz M, Freilich J, Vertuani S, Holm B, Lindman H. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. Br J Cancer. 2022;127(4):720–5. 10.1038/s41416-022-01845-z . Epub 2022 May 21. PMID: 35597870; PMCID: PMC9381497. Zeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis Onc. 2023;7:16. https://doi.org/10.1038/s41698-023-00353-4 . Raisi-Estabragh Z, Manisty CH, Cheng RK, Lopez Fernandez T, Mamas MA. Burden and prognostic impact of cardiovascular disease in patients with cancer. Heart. 2023;109(24):1819–26. 10.1136/heartjnl-2022-321324 . Published 2023 Nov 27. Youn JC, Chung WB, Ezekowitz JA, et al. Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. Int J Cardiol. 2020;317:167–73. 10.1016/j.ijcard.2020.04.080 . Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122–30. 10.1200/JCO.2015.64.0409 . Matetic A, Mohamed M, Miller RJH, et al. Impact of cancer diagnosis on causes and outcomes of 5.9 million US patients with cardiovascular admissions. Int J Cardiol. 2021;341:76–83. 10.1016/j.ijcard.2021.07.054 . Kobo O, Moledina SM, Raisi-Estabragh Z, et al. Emergency department cardiovascular disease encounters and associated mortality in patients with cancer: A study of 20.6 million records from the USA. Int J Cardiol. 2022;363:210–7. 10.1016/j.ijcard.2022.06.053 . Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, Dos-Santos-Silva I, Smeeth L, Bhaskaran K. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041–54. 10.1016/S0140-6736(19)31674-5 . Epub 2019 Aug 20. PMID: 31443926; PMCID: PMC6857444. Raisi-Estabragh Z, Cooper J, McCracken C, et al. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart. 2023;109:1007–15. Kobo O, Raisi-Estabragh Z, Gevaert S, et al. Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 and 2017. Eur Heart J Qual Care Clin Outcomes. 2022;8:787–97. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 31 Dec, 2024 Read the published version in Cardio-Oncology → Version 1 posted Editorial decision: Revision requested 17 Dec, 2024 Reviews received at journal 10 Nov, 2024 Reviewers agreed at journal 10 Nov, 2024 Reviewers invited by journal 06 Sep, 2024 Editor assigned by journal 29 Aug, 2024 Submission checks completed at journal 27 Aug, 2024 First submitted to journal 22 Aug, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4959562","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":352754550,"identity":"4cdbc61f-9d0a-474b-b52f-e87bdd2d6cd9","order_by":0,"name":"Hisham A. Badreldin","email":"","orcid":"","institution":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","correspondingAuthor":false,"prefix":"","firstName":"Hisham","middleName":"A.","lastName":"Badreldin","suffix":""},{"id":352754551,"identity":"5b0cb991-8b9f-4122-ac34-d252e9ae4632","order_by":1,"name":"Nada Alsuhebany","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7ElEQVRIiWNgGAWjYFAC5gYGxgaGBCCL8QGQ4OEjrIURroXZAKSFjRQtbBIgPkEt5uwHmz/z7rDJ45/dY1b5NcdOho2B+eGjG3i0WPYktknznkkrlrhzxuy27LZkoMPYjI1z8GgxOJDYxszbdjix4UaO2W3JbcxALTxs0ni1nH8IdFjb/8T5QC3FktvqidByI7FBmrftQOIGoBbGj9sOE6PlYZvk3LbkYsMbacXSjNuO87AxE/LL+eTDH9622eXJ3Uje+PHntmp7fvbmh4/xaUECHAbMPCCamTjlIMD+gPEH8apHwSgYBaNgBAEAfBlLPFUg2PAAAAAASUVORK5CYII=","orcid":"","institution":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","correspondingAuthor":true,"prefix":"","firstName":"Nada","middleName":"","lastName":"Alsuhebany","suffix":""},{"id":352754552,"identity":"21b5d0a7-9c56-4356-b647-92f21f5419dd","order_by":2,"name":"Lama Alfehaid","email":"","orcid":"","institution":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","correspondingAuthor":false,"prefix":"","firstName":"Lama","middleName":"","lastName":"Alfehaid","suffix":""},{"id":352754553,"identity":"6a727b81-b024-4308-9480-9e5ef76b28e5","order_by":3,"name":"Mohammed Alzahrani","email":"","orcid":"","institution":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","correspondingAuthor":false,"prefix":"","firstName":"Mohammed","middleName":"","lastName":"Alzahrani","suffix":""},{"id":352754554,"identity":"415b11b2-a8bf-4b81-8a78-6699f5da7b59","order_by":4,"name":"Maha Aldoughaim","email":"","orcid":"","institution":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","correspondingAuthor":false,"prefix":"","firstName":"Maha","middleName":"","lastName":"Aldoughaim","suffix":""},{"id":352754555,"identity":"446d088f-7995-487d-87cd-4cb56d63c5a0","order_by":5,"name":"Abdullah M. Alrajhi","email":"","orcid":"","institution":"Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia","correspondingAuthor":false,"prefix":"","firstName":"Abdullah","middleName":"M.","lastName":"Alrajhi","suffix":""},{"id":352754556,"identity":"8ec0ba7e-f253-46a9-ad54-3a0a5a2aa3fc","order_by":6,"name":"Jumanah Alsufyani","email":"","orcid":"","institution":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","correspondingAuthor":false,"prefix":"","firstName":"Jumanah","middleName":"","lastName":"Alsufyani","suffix":""},{"id":352754557,"identity":"808f9432-52c7-49c4-99a6-22cd8b6ce3fe","order_by":7,"name":"Dania Elsherif","email":"","orcid":"","institution":"College of Pharmacy, University of Medical Sciences and Technology","correspondingAuthor":false,"prefix":"","firstName":"Dania","middleName":"","lastName":"Elsherif","suffix":""},{"id":352754558,"identity":"357b860b-7c44-489e-b8c3-6d95a7c6f19f","order_by":8,"name":"Kanan Alshammari","email":"","orcid":"","institution":"Department of Medical Oncology, Ministry of National Guard Health Affairs","correspondingAuthor":false,"prefix":"","firstName":"Kanan","middleName":"","lastName":"Alshammari","suffix":""}],"badges":[],"createdAt":"2024-08-22 16:55:52","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4959562/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4959562/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s40959-024-00299-x","type":"published","date":"2024-12-31T15:57:39+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":66863527,"identity":"f7ca3fe0-a1b4-469d-903a-8cde38e0bac3","added_by":"auto","created_at":"2024-10-17 08:47:18","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":383515,"visible":true,"origin":"","legend":"\u003cp\u003eThe percentage of perception of cardio-oncology by respondents\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-4959562/v1/ed0d9a83c2db3554134f2a5d.png"},{"id":66863526,"identity":"925ebc10-5174-44b0-9d29-23d1b4da2d97","added_by":"auto","created_at":"2024-10-17 08:47:18","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":33500,"visible":true,"origin":"","legend":"\u003cp\u003eThe percentage of guidelines familiarity reported by respondents\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-4959562/v1/854de4b4452647ed7427f8e7.png"},{"id":66863528,"identity":"09590d4b-1bf8-4522-b449-e9b8a0459e5e","added_by":"auto","created_at":"2024-10-17 08:47:18","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":253058,"visible":true,"origin":"","legend":"\u003cp\u003eAcceptable risk of cardiotoxicity: Risk tolerance of cardiotoxicity in the metastatic setting\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-4959562/v1/b7507f620e4e9c4d6935b74b.png"},{"id":73094156,"identity":"ba6115bf-f301-4dec-ac55-b92aad866b26","added_by":"auto","created_at":"2025-01-06 16:23:17","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1222517,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4959562/v1/9451380a-85b5-41ed-bc7b-64d2a2e2b7b6.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Assessment of Cardio-Oncology Knowledge and Practice among Healthcare Providers in Saudi Arabia: A Comprehensive Nationwide Survey","fulltext":[{"header":"Introduction","content":"\u003cp\u003eThe oncology field is witnessing a rapid evolution in systemic therapy regimens and guidelines globally[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. In 2020 alone, 17,631 newly diagnosed cases of cancer were reported to the Saudi Cancer Registry, with the most common being breast, colorectal then thyroid cancers[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. With improvements in cancer management resulting in decreasing cancer-related mortality rates, the management of cardiovascular diseases and accessibility to cardiovascular care have become increasingly paramount[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Despite advancements in medical care, cancer and cardiovascular diseases remain prominent causes of mortality globally[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAs cancer and cardiovascular disease both share similar risk factors, such as increasing age, smoking, alcohol use, and high BMI[\u003cspan additionalcitationids=\"CR6 CR7\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e], this contributes to the rising prevalence of both diseases. This is further complicated by the fact that it has been well-established that cancer treatments can cause cancer treatment-related cardiovascular toxicity (CTR-CVT)[\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Since then, it has been suggested that cardiotoxic cancer medications can be divided into drugs that can potentially cause irreversible damage (Type I) and drugs that predominantly induce reversible dysfunction (Type II)[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCardio-oncology has emerged as an expanding specialty dedicated to providing cardiovascular care for both active cancer patients and cancer survivors in direct response to the increasing requirements of this population[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. The scope of cardio-oncology encompasses optimizing pre-cancer treatment, diagnosing, and managing cardiac complications resulting from cancer treatment both during and after the completion of cancer therapy. Although numerous cardio-oncology programs have emerged to address these demands, they remain predominantly confined to larger institutions, often serving as academic referral centers.\u003c/p\u003e \u003cp\u003eOver the years, several international organizations, including the American Society of Clinical Oncology (ASCO), the European Society of Cardiology (ESC), and the National Comprehensive Cancer Network (NCCN), have issued several position statements and guidelines pertaining to the detection and management of cancer treatment-related cardiac dysfunction (CTRCD)[\u003cspan additionalcitationids=\"CR12\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. However, cardio-oncology is still an emerging field. Due to a lack of training programs, it is unclear how well-trained healthcare providers (HCPs) are in this subspecialty. In a survey of 106 cardiovascular specialists in the United States, published in the Journal of American College of Cardiology, over 43% of respondents had no dedicated cardio-oncology training programs for cardiology fellows in their institutions[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNotably, in Saudi Arabia, cardio-oncology programs have been limitedly implemented thus far, and few to no formal training programs in the field are available. Thus, this research aims to assess the practical knowledge of HCPs, including cardiologists, oncologists, and clinical pharmacists, on cardio-oncology in Saudi Arabia. This would inform healthcare providers on how to better improve the quality of life of their patients and the care provided to them.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy Design and Subjects\u003c/h2\u003e \u003cp\u003eA cross-sectional study was conducted in Saudi Arabia between January 2024 and April 2024. An online survey was created in English using Google Forms and distributed via email and social media platforms such as WhatsApp platform. The survey targeted physicians and clinical pharmacists specializing in oncology or cardiology. The survey was accompanied by a cover letter that described the research study's objective and targeted population, and participants were given access to the survey after accepting participation. The survey was created by two oncologists and two cardiologists specializing in cardio-oncology. It had been previously validated and used internationally in a study conducted by Peng et al. in 2019. The survey was obtained with the corresponding author's permission[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. The study received Institutional Review Board (IRB) approval from King Abdullah International Medical Research Center at National Guard Health Affairs in Riyadh, Saudi Arabia (IRB/2930/23).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eQuestionnaire Items\u003c/h2\u003e \u003cp\u003eThe survey comprised seven sections, including multiple-choice and Likert scale questions and two clinical scenarios. It consisted of a total of 45 questions, with 13 of them for oncologists and five for cardiologists. The first section collected the participants\u0026rsquo; demographics and respondents. The second section evaluated the participants\u0026rsquo; perceptions of cardio-oncology, for instance, inquiring about one\u0026rsquo;s definition of \u0026ldquo;cardio-oncology\u0026rdquo;. The third section assessed the availability of cardio-oncology services at participants\u0026rsquo; institutions. The fourth section collected opinions regarding the current practices in the cardio-oncology field. It aimed to evaluate the perceived importance of oncologists in considering cardiotoxicity during different stages of cancer therapy, such as planning, utilization, and completion, and how it affects their decision-making processes. It also assessed participants\u0026rsquo; opinions on whether cancer patients would benefit from cardiologists' involvement and cardio-oncology clinics. The fifth section of the questionnaire is directed explicitly to cardiologists. This section assessed cardiologists' knowledge and comfort level in recognizing and managing cardiotoxicity. Additionally, it aimed to determine their perception of the skills and expertise possessed by their oncology colleagues in dealing with cardiotoxicity-related issues. The following section of the questionnaire was designed solely for oncologists to assess their knowledge and comfort level in identifying and managing cardiotoxicity. In addition, it aimed to determine their perspective on the skill of their cardiology colleagues in dealing with cardiotoxicity-related cancer therapy. The last section presented two clinical scenarios of common cardiotoxicity issues in oncology to assess participants' ability to apply their knowledge.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eDescriptive quantitative analysis was generated via the \u0026ldquo;response\u0026rdquo; feature in Google Forms. Chi-squared test was used to compare categorical variables, and bivariate analysis was used to examine associations between the dependent and independent variables. The response rate was not obtainable, given the survey was distributed online. Statistical analyses were conducted using Excel software version 16.88.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eDemographics of respondents and experience in practice\u003c/h2\u003e \u003cp\u003eA total of 116 HCPs in Saudi Arabia participated in the survey. Most respondents were cardiologists (63.79%), followed by oncologists (23.28%), and clinical pharmacists specializing in cardiology and oncology (12.93%). Nearly more than half of the respondents were from the central region of Saudi Arabia (67.24%). The majority of participants had over six years of experience (80.68%). Out of the respondents, only one physician received formal training in cardio-oncology. Additionally, 87.07% of the practitioners worked in tertiary hospitals (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDemographics of healthcare professionals surveyed (n\u0026thinsp;=\u0026thinsp;116)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRegion\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCentral region\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e67.24\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEastern region\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15.52\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWestern region\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9.48\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNorthern region\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSouthern region\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.31\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSpecialty\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiology phis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOncology/hematology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClinical Pharmacist in cardiology field\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.90\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClinical Pharmacist in oncology/hematology field\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.03\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCurrent position\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eConsultant (physician or pharmacist)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e48.35\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStaff physician\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.40\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSenior pharmacist\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.75\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFellow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.59\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedical Resident\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.65\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eYears practice of consultant (physician or pharmacist)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u0026ndash;5 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19.32\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u0026ndash;10 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21.59\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e11\u0026ndash;20 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36.36\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;20 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22.73\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePractice location description\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTertiary care hospital\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e101\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e87.07\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSecondary hospital\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9.48\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrivate clinic/hospital\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePercentage of time spent on clinical research\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLess than 10%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e51.72\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u0026ndash;20%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26.72\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e20\u0026ndash;30%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12.93\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e30\u0026ndash;40%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e40\u0026ndash;50%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.86\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMore than 50%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4.31\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePerception of cardio-oncology and cardiotoxicity\u003c/h2\u003e \u003cp\u003eRegarding the HCP\u0026rsquo;s perception towards cardio-oncology, the respondents had the chance to respond to this question with multiple choice questions where multiple answers were accepted. The majority of respondents believed cardio-oncology means managing cancer patients who are experiencing cardiac complications secondary to cancer therapy (84.48%). Furthermore, more than (80%) believed cardio-oncology is about recognizing patients at high risk of developing cardiotoxicity from cancer treatment and diagnosing cardiotoxicity induced by cancer treatment (83.62 and 82.76%, respectively) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eRegarding the HCPs perception towards the most significant risk of cardiotoxicity induced by cancer treatment,=70.69%) of respondents believe that targeted agents (such as trastuzumab) induced cardiotoxicity could be experienced during cancer treatment. In addition, 56.90% believe that chemotherapy-induced cardiotoxicity could develop during cancer treatment (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePerceptions of cardiotoxicity risk\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eThe greatest risk of experiencing cardiotoxicity from chemotherapy (e.g. anthracyclines), n (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuring cancer treatment (chemotherapy and/or targeted agents)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e66 (56.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOne-year post-cancer therapy (short-term risk)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e42 (36.21)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOne to five years post-cancer therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e48 (41.38)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGreater than five years post-cancer therapy (long-term risk)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e52 (44.83)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eThe greatest risk of experiencing cardiotoxicity from targeted therapies (e.g. trastuzumab), n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuring cancer treatment (chemotherapy and/or targeted agents)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e82 (70.69)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOne year post-cancer therapy (short-term risk)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26 (22.42)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOne to five years post-cancer therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39 (33.63)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGreater than five years post-cancer therapy (long-term risk)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32 (27.59)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e Almost 42.24% of respondents reported being familiar with guidelines from expert societies on the directions and management of cardiovascular toxicity. Out of the reported societies, the ESC was the most recognized guideline (58.93%) by the respondents (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eAvailability of cardio-oncology services at respondents' institution\u003c/h2\u003e \u003cp\u003eThis survey assessed the availability of educational programs in cardio-oncology. The most frequent answer regarding educational programs was \u0026ldquo;there is little cardiology training for clinical cardiology fellows\u0026rdquo; (36.21%). Interestingly, 31.9% of respondents reported the lack of program availability at all. Regarding cardio-oncology services offered currently at respondents' institutions, almost half of the respondents reported providing such services on a consultation-based model (55.18%). Reflecting on the potential obstacles to the development of cardio-oncology units, \u0026ldquo;limited interest\u0026rdquo; was the most frequent answer (40.52%) reported by the respondents, followed by \u0026ldquo;limited funding\u0026rdquo; and \u0026ldquo;limited infrastructure\u0026rdquo; (28.45%, 25%) (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAvailability of cardio-oncology services at respondents' institution\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eEducation programs are available in the field of cardio-oncology, n (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThere is little cardio-oncology training for clinical cardiology fellows\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e42 (36.21)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiology fellows are exposed to cardio-oncology during clinical rotations as part of the curriculum\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (7.76)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThere are some lectures on cardio-oncology as part of the core curriculum or CME offerings\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e22 (18.97)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiology fellows can choose to spend time training with the oncology service, but this is not part of the core curriculum\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (5.18)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThere is a dedicated cardio-oncology fellowship program (at least 6 months)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.87)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eI am unsure of available cardio-oncology programs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e38 (32.76)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo available programs at all\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37 (31.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCardio-oncology services are currently offered\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eConsultation service operated by general cardiologists for assessment and management of cardiotoxicity among cancer patients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e64 (55.18)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePhysicians specialized in the field of cardio-oncology who are comfortable managing cardio-toxic side effects due to cancer therapy and can give recommendations for adjusting cancer therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2.59)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClinical pharmacists in the field of cardio-oncology who are comfortable managing cardio-toxic side effects due to cancer therapy and can give recommendations for adjusting cancer therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (4.32)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardio-oncology services are not currently present and there are no plans to add these services\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (8.63)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardio-oncology services are not currently present but there are plans to add these services within the year\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 (6.04)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eI am unsure of the available services\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27 (23.28)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePotential obstacles to the development of cardio-oncology units\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLimited funding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e33 (28.45)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLimited infrastructure\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29 (25)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLimited need\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 (6.04)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLimited interest\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e47 (40.52)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo obstacle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32 (27.59)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eRespondents' opinions towards current practice\u003c/h2\u003e \u003cp\u003eIn the current study, both cardiologists and oncologists agreed on the importance of oncologists' consideration of cardiotoxicity when planning treatment plans (82.93% and 79.41% respectively). Furthermore, both specialist groups agreed on the importance of monitoring for possible cardiac adverse events during active cancer treatments (85.37% and 76.47% respectively). For cancer survivors, both groups agreed that oncologists should consider possible cardiac complications induced by cancer treatment exposure (58.54% and 55.88 respectively). Half of the respondents believed in the involvement of cardiologists in providing ongoing monitoring for cardiotoxicity, even if the patient has no clinical symptoms of cardiac issues. On a scale of 5, 34.15% of cardiologists strongly agree on using cardioprotective agents as a standard of care while 35% of oncologists were neutral about this statement. The majority of respondents (87.93%) thought that access to cardio-oncology services would not change the prognosis of cancer patients. In the setting of metastatic cancer, more cardiologists (7.32%) accepted a higher risk of cardiotoxicity (\u0026gt;\u0026thinsp;15% risk) compared to oncologists (0%) (\u003cb\u003eFigure. 3\u003c/b\u003e), However, both oncologists and cardiologists accepted cardiotoxicity ranging between 5\u0026ndash;15%.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eCurrent Practice of Respondents\u003c/h2\u003e \u003cp\u003eCardiologists' responses to the statement \u0026ldquo;I am knowledgeable about cardiovascular complications of cancer therapy\u0026rdquo; were mostly neutral (41.46%) followed by agreement (37.80%). There was an agreement among cardiologists about their comfort in treating cardiovascular complications induced by cancer therapy, where most of them responded as neutral, agree, and strongly agree (28.05%, 32.93%, and 25.61%, respectively). In addition to that, cardiologists' responses were mostly neutral when asked how oncologists are knowledgeable and comfortable with managing cardiovascular toxicities of cancer therapy (42.68% and 31.71%, respectively). Almost 40% of cardiologists reported that they sometimes prescribe cardiac medications to manage patients with cardiotoxicities as a result of cancer therapy.\u003c/p\u003e \u003cp\u003eWhen it comes to oncologists' practice, almost 70% of oncologists feel comfortable treating cardiovascular toxicities induced by cancer therapy. In addition to that, 50% of them feel comfortable managing such cases. Furthermore, 44.12% of oncologists were neutral when asked \u0026ldquo;whether cardiologists are knowledgeable about these toxicities\u0026rdquo; and 35.29% agreed that cardiologists are comfortable managing such cases., Moreover, 33.8% of oncologists responded that they ask all cancer patients about cardiovascular risk factors prior to starting any cancer therapy. Similar to cardiologists, almost 40% of oncologists reported that they sometimes prescribe cardiac medications to patients with cardiovascular toxicities.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe advancements in cancer therapy in recent years have contributed to increased overall survival in various cancer types, creating a population with emerging medical needs, including cardio-oncology care[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Several studies have been conducted to describe the cardio-oncology landscape among patients with cancer in Saudi Arabia. A single-center retrospective analysis that was conducted in Najran identified cardiac toxicity in around 15% of their cancer patient population[\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Similarly, a larger retrospective analysis by Aljazairi and colleagues included over 1000 patients who received trastuzumab, pertuzumab, and bevacizumab; cardiovascular toxicities were detected in around 16% of their patient population[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. A recent guideline update by the Saudi Heart Association expanded recommendations to focus on special populations, including oncology patients, to further accommodate the growing needs of patients living with cancer[\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. To our knowledge, this study is the first to capture the current state of cardio-oncology practices among healthcare providers in Saudi Arabia to help address knowledge gaps, educational and training needs in the country.\u003c/p\u003e \u003cp\u003eOur survey was completed by 116 HCPs, most of whom were cardiology specialists. Most respondents had over five years of clinical experience and practiced in tertiary care institutions. Notably, out of the 116 responders, only one physician received formal cardio-oncology training, which reflects the current limited state of exposure to the field during residency and fellowship training. Most respondents were able to identify the growing role of cardio-oncology care and the major cardiovascular offenders, such as trastuzumab and anthracyclines. On the other hand, less than half of the respondents identified relevant information sources to refer back to, which is a considerable limitation to the provision of cardio-oncology care. This can be improved by setting institutional practice guidelines and introducing national and international practice guidelines in the field of cardio-oncology in training programs and academic curriculums. The American College of Cardiology established a framework for cardio-oncology subspecialty fellowship programs; it outlines the different levels of competency a program should offer, which range from a basic understanding of cardio-oncology concepts to rigorous coverage in cardio-oncology specialized clinics[\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Multiple healthcare systems in the United States have shared successful experiences in implementing specialized training programs; several aspects can be adopted in Saudi Arabia, such as cross-training in specialized institutions and increasing focus on multidisciplinary care models[\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe survey our study was adopted from Peng et al study, hence we compared results of our study Peng et al[\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] which reveals several important similarities, and differences. While our study focused on a specific region, Saudi Arabia, and targeted cardiologists and oncologists, Peng et al.'s study had a broader geographic scope, including participants from 22 countries across multiple continents. This broader scope allowed Peng et al. to capture a more diverse range of practices and opinions, while our study provided a more focused insight into the cardio-oncology landscape within Saudi Arabia. In terms of demographics, both studies reported a higher participation rate among cardiologists than oncologists. When comparing perceptions of cardio-oncology and cardiotoxicity, both studies revealed that the majority of respondents recognized the importance of managing cardiac complications secondary to cancer therapy and the need for cardiologists' involvement in cancer care. However, Peng et al. found a more significant disparity between cardiologists and oncologists regarding when and how cardiologists should be involved in cancer patient care. Moreover, the availability of cardio-oncology services and training programs was a common concern in both studies. Peng et al. highlighted limited funding and infrastructure as significant barriers to the development of cardio-oncology clinics globally, whereas our study found that limited interest was a major obstacle in Saudi Arabia.\u003c/p\u003e \u003cp\u003eFurthermore, the majority of respondents have highlighted the limited cardio-oncology services at their respective institutions. The barriers to establishing a specialized service were thought to be limited financial and administrative resources. Recommendations from a consolidated framework for implementation research (CFIR) model performed at an academic medical center in the United States may be utilized to help guide the implementation of cardio-oncology services in Saudi Arabia; this includes standardization of referral processes and integrating decision-making tools in electronic health records[\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Another positive experience in implementing specialized cardio-oncology services was reported by the Iraqi Cardio-Oncology Program-Pharmacist (ICOP-Pharm). The ICOP model integrates experienced clinical pharmacists in direct patient care as a part of a multidisciplinary care team; this allowed better drug therapy optimization and helped cardiologists manage a larger number of patients[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eMetastatic cancer disease survival has increased significantly over the last few years in which common cancer diseases such as metastatic colorectal, and breast cancers have median survival of more than 2\u0026ndash;3 years[\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. The results of our study indicate that in the setting of metastatic cancer, a higher percentage of cardiologists were willing to accept a cardiotoxicity risk greater than 15%, whereas none of the oncologists were willing to accept this level of risk. This finding is particularly noteworthy as it suggests that oncologists may be less willing to accept higher cardiotoxicity risks in these patients because many of them can maintain a good quality of life during their extended survival period. In contrast, cardiologists might be more inclined to accept higher risks, potentially due to limited awareness of the significant improvements in survival rates and quality of life for these patients. This difference in perception demonstrates the need for better interdisciplinary communication and education to align treatment goals and risk assessments between cardiologists and oncologists, ensuring that patients receive the most appropriate care tailored to their long-term survival prospects.\u003c/p\u003e \u003cp\u003eSurvey domains evaluating current practices have shown a general agreement on considering potential cardiotoxicities in oncology patients and the involvement of cardiology in managing patients who develop toxicities. However, one-third of respondents actively recommend cardioprotective agents in the care process. The described practice is consistent with the ESC cardio-oncology guidelines, which suggests only considering cardioprotective strategies in high-risk subsets of patients based on small clinical trials[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Surprisingly, over 80% of responders thought that cardio-oncology care will not change cancer prognosis. In addition, there seems to be a gap in cardiovascular risk factor screenings in oncology patients undergoing therapy. These interesting results indicate that cancer and cardiovascular disease are viewed as separate disease states rather than a part of the oncology disease continuum; this further confirms the need for robust cardio-oncology services since several large studies have shown increased cardiovascular disease incidence and mortality in patients with cancer compared to the general population[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan additionalcitationids=\"CR28 CR29 CR30 CR31 CR32 CR33\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThis nationwide study has several limitations. First, the survey was distributed on a large scale via link distribution, limiting our ability to assess the survey response rate. The majority of respondents were practicing in academic and tertiary care centers in the central region of Saudi Arabia, which limits the generalizability of these results to smaller healthcare settings.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe study highlights a significant knowledge gap and limited exposure to cardio-oncology among HCPs in Saudi Arabia. Despite recognizing the importance of managing cardiotoxicity in cancer patients, formal training and comprehensive cardio-oncology services remain limited. Implementing institutional guidelines, integrating cardio-oncology into medical education, and adopting multidisciplinary care models are essential to improve patient outcomes and address the growing needs of cancer patients at risk of cardiovascular complications.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003cstrong\u003eEthical Approval\u003c/strong\u003e \u003cp\u003eThe study received Institutional Review Board (IRB) approval from King Abdullah International Medical Research Center at National Guard Health Affairs in Riyadh, Saudi Arabia (IRB/2930/23). All participants consented when they filled out the survey.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eNo financial support of any form was received in connection with this study.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eHAB contributed to the concept of the research; NA distributed the survey and wrote the abstract, introduction, discussion, and conclusion. also, has critiqued the whole manuscript; LA distributed the survey and wrote the method part, and critiqued the whole manuscript; MAZ did the analysis and wrote the result part; MAD wrote the discussion part; AMA distributed the survey, and critiqued the whole manuscript; JA distributed the survey, and wrote the method part; DE distributed the survey, and wrote the introduction part; KA distributed the survey, and critiqued the whole manuscript; AND all authors reviewed the submitted manuscript\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eThe data that support the findings of this study are available from the corresponding author on reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eHerrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J. 2019;40:3898\u0026ndash;900. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/eurheartj/ehz781\u003c/span\u003e\u003cspan address=\"10.1093/eurheartj/ehz781\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSaudi Cancer Registry. Cancer Incidence Report in Saudi Arabia. Ministry of Health; 2020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSturgeon KN, Deng L, Bluethman SL, et al. A population based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u0026ndash;97. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/eurheartj/ehz766\u003c/span\u003e\u003cspan address=\"10.1093/eurheartj/ehz766\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGlobal Health Estimates. 2019: Deaths by Cause, Age, Sex, by Country and by Region, 2000\u0026ndash;2019. Geneva, World Health Organization; 2020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTran K, Bao et al. The global burden of cancer attributable to risk factors, 2010\u0026ndash;19: a systematic analysis for the Global Burden of Disease Study 2019.\u003cem\u003eLancet\u003c/em\u003e, Volume 400, Issue 10352, 563\u0026ndash;591.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. \u003cem\u003eLancet.\u003c/em\u003e 2004 Sep 11\u0026ndash;17;364(9438):937\u0026thinsp;\u0026ndash;\u0026thinsp;52. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(04)17018-9\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(04)17018-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 15364185.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNorth BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097\u0026ndash;108. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/CIRCRESAHA.111.246876\u003c/span\u003e\u003cspan address=\"10.1161/CIRCRESAHA.111.246876\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 22499900; PMCID: PMC3366686.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVon Hoff DD, Layard MW, Basa P, Jr DAVIS, Von Hoff HL, Rozencweig AL, M., Muggia FM. Risk factors for doxorubicin-lnduced congestive heart failure. Ann Intern Med. 1979;91(5):710\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEwer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. \u003cem\u003eJ Clin Oncol.\u003c/em\u003e 2005;23(31):7820-6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.2005.13.300\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2005.13.300\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 16258084.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEwer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. \u003cem\u003eJ Clin Oncol.\u003c/em\u003e 2005;23(13):2900-2. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.2005.05.827\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2005.05.827\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. PMID: 15860848.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSaro H, Armenian et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. \u003cem\u003eJCO\u003c/em\u003e 35, 893\u0026ndash;911(2017). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.2016.70.5400\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2016.70.5400\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLyon AR, L\u0026oacute;pez-Fern\u0026aacute;ndez T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J. 2023;44(18):1621. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/eurheartj/ehad196]\u003c/span\u003e\u003cspan address=\"10.1093/eurheartj/ehad196]\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Eur Heart J. 2022;43(41):4229\u0026ndash;4361. doi:10.1093/eurheartj/ehac244.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCardiovascular Health and Risk Management in Cancer Survivors. (2020). Journal of the National Comprehensive Cancer Network. \u003cem\u003eJ Natl Compr Canc Netw\u003c/em\u003e, 18(7.5), 1004\u0026ndash;1006. Retrieved Mar 25, 2024, from \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.6004/jnccn.2020.5004\u003c/span\u003e\u003cspan address=\"10.6004/jnccn.2020.5004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarac A, Murtagh G, Carver J, et al. Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol. 2015 Jun;65(25):2739\u0026ndash;46. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jacc.2015.04.059\u003c/span\u003e\u003cspan address=\"10.1016/j.jacc.2015.04.059\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng J, Rushton M, Johnson C, et al. An international survey of healthcare providers' knowledge of cardiac complications of cancer treatments. Cardiooncology. 2019;5:12. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s40959-019-0049-2\u003c/span\u003e\u003cspan address=\"10.1186/s40959-019-0049-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2019 Sep 2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889\u0026ndash;97. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/eurheartj/ehz766\u003c/span\u003e\u003cspan address=\"10.1093/eurheartj/ehz766\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBadheeb AM, Ahmed F, Alzahrani HA, Badheeb MA, Obied HY, Seada IA. Cancer Therapy-Related Cardiotoxicity: A Comprehensive Retrospective Analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7759/cureus.41287\u003c/span\u003e\u003cspan address=\"10.7759/cureus.41287\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2023 Jul 2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAl-Jazairi AS, Bahammam N, Aljuaid D et al. Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system. Cardiooncology. 2023;9(1):35. Published 2023 Sep 25. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s40959-023-00184-z\u003c/span\u003e\u003cspan address=\"10.1186/s40959-023-00184-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAl Habeeb W, Tash A, Elasfar A, et al. 2023 National Heart Center/Saudi Heart Association Focused Update of the 2019 Saudi Heart Association Guidelines for the Management of Heart Failure. J Saudi Heart Assoc. 2023;35(1):71\u0026ndash;134. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.37616/2212-5043.1334\u003c/span\u003e\u003cspan address=\"10.37616/2212-5043.1334\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2023 May 25.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlvarez-Cardona JA, Ray J, Carver J, et al. Cardio-Oncology Education and Training: JACC Council Perspectives. J Am Coll Cardiol. 2020;76(19):2267\u0026ndash;81. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jacc.2020.08.079\u003c/span\u003e\u003cspan address=\"10.1016/j.jacc.2020.08.079\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFradley MG. Cardio-Oncology Fellowship Training and Education. Curr Treat Options Cardiovasc Med. 2019;21(6):27. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11936-019-0733-4\u003c/span\u003e\u003cspan address=\"10.1007/s11936-019-0733-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2019 May 18.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTuzovic M, Brown SA, Yang EH, et al. Implementation of Cardio-Oncology Training for Cardiology Fellows. JACC CardioOncol. 2020;2(5):795\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaccao.2020.11.003\u003c/span\u003e\u003cspan address=\"10.1016/j.jaccao.2020.11.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2020 Dec 15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClouser JM, McMullen CA, Adu AK, Wells G, Arbune A, Li J. Using the consolidated framework for implementation research (CFIR) to guide implementation of cardio-oncology services. Learn Health Syst. 2023;8(2):e10402. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/lrh2.10402\u003c/span\u003e\u003cspan address=\"10.1002/lrh2.10402\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2023 Dec 13.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYaseen IF, Farhan HA. Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study. Front Cardiovasc Med. 2022;9:972455. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fcvm.2022.972455\u003c/span\u003e\u003cspan address=\"10.3389/fcvm.2022.972455\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2022 Sep 29.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eValachis A, Carlqvist P, Ma Y, Szilcz M, Freilich J, Vertuani S, Holm B, Lindman H. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. Br J Cancer. 2022;127(4):720\u0026ndash;5. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41416-022-01845-z\u003c/span\u003e\u003cspan address=\"10.1038/s41416-022-01845-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2022 May 21. PMID: 35597870; PMCID: PMC9381497.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis Onc. 2023;7:16. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41698-023-00353-4\u003c/span\u003e\u003cspan address=\"10.1038/s41698-023-00353-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRaisi-Estabragh Z, Manisty CH, Cheng RK, Lopez Fernandez T, Mamas MA. Burden and prognostic impact of cardiovascular disease in patients with cancer. Heart. 2023;109(24):1819\u0026ndash;26. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/heartjnl-2022-321324\u003c/span\u003e\u003cspan address=\"10.1136/heartjnl-2022-321324\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Published 2023 Nov 27.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYoun JC, Chung WB, Ezekowitz JA, et al. Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. Int J Cardiol. 2020;317:167\u0026ndash;73. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ijcard.2020.04.080\u003c/span\u003e\u003cspan address=\"10.1016/j.ijcard.2020.04.080\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArmenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122\u0026ndash;30. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.2015.64.0409\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2015.64.0409\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMatetic A, Mohamed M, Miller RJH, et al. Impact of cancer diagnosis on causes and outcomes of 5.9 million US patients with cardiovascular admissions. Int J Cardiol. 2021;341:76\u0026ndash;83. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ijcard.2021.07.054\u003c/span\u003e\u003cspan address=\"10.1016/j.ijcard.2021.07.054\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKobo O, Moledina SM, Raisi-Estabragh Z, et al. Emergency department cardiovascular disease encounters and associated mortality in patients with cancer: A study of 20.6 million records from the USA. Int J Cardiol. 2022;363:210\u0026ndash;7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ijcard.2022.06.053\u003c/span\u003e\u003cspan address=\"10.1016/j.ijcard.2022.06.053\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStrongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, Dos-Santos-Silva I, Smeeth L, Bhaskaran K. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041\u0026ndash;54. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(19)31674-5\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(19)31674-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2019 Aug 20. PMID: 31443926; PMCID: PMC6857444.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRaisi-Estabragh Z, Cooper J, McCracken C, et al. Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart. 2023;109:1007\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKobo O, Raisi-Estabragh Z, Gevaert S, et al. Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 and 2017. Eur Heart J Qual Care Clin Outcomes. 2022;8:787\u0026ndash;97.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"cardio-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"caon","sideBox":"Learn more about [Cardio-Oncology](http://cardiooncologyjournal.biomedcentral.com)","snPcode":"40959","submissionUrl":"https://submission.nature.com/new-submission/40959/3","title":"Cardio-Oncology","twitterHandle":"@OncoBioMed","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-4959562/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4959562/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eIntroduction: \u003c/strong\u003eThe evolving field of oncology necessitates effective management of cancer-related cardiovascular diseases. In Saudi Arabia, the incidence of cancer is rising, and there is a critical need for cardio-oncology services to address cancer treatment-related cardiovascular toxicity. This study aimed to evaluate the knowledge and practices of healthcare providers (HCPs) in Saudi Arabia regarding cardio-oncology.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eA cross-sectional study was conducted from January to April 2024 using an online survey targeting cardiologists, oncologists, and clinical pharmacists. The survey assessed demographics, perceptions of cardio-oncology, availability of services, and current practices. Data were analyzed using descriptive statistics, chi-squared tests, and bivariate analyses.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eThe survey received responses from 116 HCPs, including cardiologists (63.79%), oncologists (23.28%), and clinical pharmacists (12.93%). Most participants had over six years of experience, and only one had formal cardio-oncology training. While 84.48% recognized the importance of managing cardiac complications in cancer patients, only 42.24% were familiar with existing guidelines. Limited training programs and institutional resources were significant barriers to implementing cardio-oncology services. Despite agreement on the need for cardiotoxicity management, only one-third recommended cardioprotective agents as standard care.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion: \u003c/strong\u003eThere is a notable deficiency in formal training and resources for cardio-oncology in Saudi Arabia. To bridge this gap, integrating cardio-oncology into training programs, establishing institutional guidelines, and adopting multidisciplinary care models are crucial. These measures will enhance the quality of care for cancer patients and improve their cardiovascular outcomes.\u003c/p\u003e","manuscriptTitle":"Assessment of Cardio-Oncology Knowledge and Practice among Healthcare Providers in Saudi Arabia: A Comprehensive Nationwide Survey","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-17 08:47:13","doi":"10.21203/rs.3.rs-4959562/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-12-17T17:20:11+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-11-10T07:52:21+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"291761569080551360144286053424836237985","date":"2024-11-10T05:35:10+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-09-06T19:25:17+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-08-29T19:18:58+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-08-27T12:08:40+00:00","index":"","fulltext":""},{"type":"submitted","content":"Cardio-Oncology","date":"2024-08-22T16:54:30+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"cardio-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"caon","sideBox":"Learn more about [Cardio-Oncology](http://cardiooncologyjournal.biomedcentral.com)","snPcode":"40959","submissionUrl":"https://submission.nature.com/new-submission/40959/3","title":"Cardio-Oncology","twitterHandle":"@OncoBioMed","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2f37dbe1-9cac-4f82-bd50-8528eb3455e8","owner":[],"postedDate":"October 17th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-01-06T16:21:26+00:00","versionOfRecord":{"articleIdentity":"rs-4959562","link":"https://doi.org/10.1186/s40959-024-00299-x","journal":{"identity":"cardio-oncology","isVorOnly":false,"title":"Cardio-Oncology"},"publishedOn":"2024-12-31 15:57:39","publishedOnDateReadable":"December 31st, 2024"},"versionCreatedAt":"2024-10-17 08:47:13","video":"","vorDoi":"10.1186/s40959-024-00299-x","vorDoiUrl":"https://doi.org/10.1186/s40959-024-00299-x","workflowStages":[]},"version":"v1","identity":"rs-4959562","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4959562","identity":"rs-4959562","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}